1200 AVENUE OF THE AMERICAS, NEW YORK, X1
Director Resignation - Tamar Howson Steps Down from Board
Investor Presentation
Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer
Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
Reports First Quarter 2026 Financial Results and Provides Corporate Update
Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer
Announces 1-for-10 Reverse Stock Split
Material disclosure
Q1
Amended Annual Report
FY 2024
Q3
Q2
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership